Candel Therapeutics Advances CAN-2409 Toward BLA Submission, Targeting First Commercial Product in 2027
核心洞察
Candel Therapeutics is advancing its lead candidate CAN-2409 toward a biologics license application (BLA) submission expected in the fourth quarter, with management citing "meaningful execution" toward the filing.
The clinical-stage immuno-oncology company is targeting its first commercial product launch in 2027, positioning regulatory progress as a key catalyst.
Analysts hold a consensus "Moderate Buy" rating on the stock, with HC Wainwright reaffirming a Buy rating and $23 price target while forecasting EPS of $0.69 in fiscal 2028 and $1.41 in fiscal 2029.
Candel Therapeutics (NASDAQ: CADL), a clinical-stage immuno-oncology company, is advancing its lead candidate CAN-2409 toward a biologics license application (BLA) submission expected in the fourth quarter, with management highlighting "meaningful execution" toward the filing. The company is targeting its first commercial product launch in 2027, positioning regulatory progress as a key catalyst for the stock.
Pipeline and Therapeutic Focus
Candel Therapeutics is focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. Its lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. The company leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma (搜索), and other novel viral constructs being explored for a variety of solid tumor indications. The BLA submission in the fourth quarter relates to the company's prostate cancer (搜索) candidate.
Analyst Sentiment and Price Targets
Candel Therapeutics has earned a consensus rating of "Moderate Buy" from the ten brokerages covering the firm, according to MarketBeat. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, and seven have assigned a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $19.2857.
HC Wainwright reaffirmed a "buy" rating and issued a $23.00 target price on shares of Candel Therapeutics. The firm expects Candel to become profitable in future years, forecasting EPS of $0.69 in fiscal 2028 and $1.41 in fiscal 2029. However, HC Wainwright modestly reduced its long-term EPS forecasts, cutting fiscal 2028 expectations from $0.71 to $0.69 and fiscal 2029 expectations from $1.45 to $1.41, signaling slightly lower anticipated profitability.
Bank of America raised its price target from $9.00 to $12.00 while maintaining a "neutral" rating, indicating a potential upside of 2.04% from the company's previous close. Stifel Nicolaus initiated coverage with a "buy" rating and a $22.00 price objective, while Cantor Fitzgerald began coverage with an "overweight" rating. Weiss Ratings reissued a "sell (d-)" rating on the stock.
Financial Results and Market Position
Candel Therapeutics reported a second-quarter loss of $0.52 per share, missing analysts' consensus estimates of $0.27 by $0.28. As a group, sell-side analysts predict that Candel Therapeutics will post -0.91 EPS for the current fiscal year. The earnings miss highlights continued cash burn and execution risk for the clinical-stage biotechnology company.
The company's stock opened at $11.72 on Friday, with a market capitalization of $858.72 million, a PE ratio of -8.31, and a beta of -0.51. Candel Therapeutics has a 12-month low of $4.35 and a 12-month high of $11.95. The firm's fifty-day moving average is $9.68 and its 200-day moving average is $7.40. The company maintains a quick ratio of 28.05, a current ratio of 28.05, and a debt-to-equity ratio of 0.34.
Institutional and Insider Activity
Corporate insiders own 14.30% of the company's stock, while institutional investors own 13.93%. Recent insider transactions include CTO Seshu Tyagarajan selling 7,000 shares at an average price of $10.02, representing a 7.70% decrease in ownership, and insider Francesca Barone selling 23,447 shares at an average price of $10.06, representing a 23.26% decrease in ownership.
Several institutional investors have increased their stakes, including BNP Paribas Financial Markets, which boosted its position by 128.2% during the third quarter, and Tower Research Capital LLC TRC, which increased its position by 361.7% during the second quarter.